Irbesartan y enfermedad renal crónica avanzada de causa no diabética. Estudio comparativo con IECAS
Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI
Leído
53681
Vecesse ha leído el artículo
4109
Total PDF
49572
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 447 | 52 | 499 |
| 2025 5 | 543 | 60 | 603 |
| 2025 4 | 554 | 33 | 587 |
| 2025 3 | 703 | 65 | 768 |
| 2025 2 | 625 | 38 | 663 |
| 2025 1 | 541 | 41 | 582 |
| 2024 12 | 463 | 36 | 499 |
| 2024 11 | 612 | 72 | 684 |
| 2024 10 | 561 | 63 | 624 |
| 2024 9 | 604 | 41 | 645 |
| 2024 8 | 538 | 72 | 610 |
| 2024 7 | 577 | 47 | 624 |
| 2024 6 | 528 | 66 | 594 |
| 2024 5 | 608 | 60 | 668 |
| 2024 4 | 684 | 54 | 738 |
| 2024 3 | 713 | 41 | 754 |
| 2024 2 | 769 | 42 | 811 |
| 2024 1 | 871 | 45 | 916 |
| 2023 12 | 644 | 54 | 698 |
| 2023 11 | 854 | 62 | 916 |
| 2023 10 | 872 | 78 | 950 |
| 2023 9 | 841 | 68 | 909 |
| 2023 8 | 1045 | 77 | 1122 |
| 2023 7 | 918 | 82 | 1000 |
| 2023 6 | 1087 | 84 | 1171 |
| 2023 5 | 1104 | 87 | 1191 |
| 2023 4 | 740 | 74 | 814 |
| 2023 3 | 770 | 52 | 822 |
| 2023 2 | 661 | 69 | 730 |
| 2022 1 | 483 | 44 | 527 |
| 2022 12 | 362 | 62 | 424 |
| 2022 11 | 659 | 70 | 729 |
| 2022 10 | 643 | 65 | 708 |
| 2022 9 | 638 | 51 | 689 |
| 2022 8 | 540 | 67 | 607 |
| 2022 7 | 317 | 53 | 370 |
| 2022 6 | 292 | 53 | 345 |
| 2022 5 | 328 | 74 | 402 |
| 2022 4 | 286 | 47 | 333 |
| 2022 3 | 224 | 60 | 284 |
| 2022 2 | 256 | 60 | 316 |
| 2021 1 | 286 | 67 | 353 |
| 2021 12 | 176 | 53 | 229 |
| 2021 11 | 240 | 63 | 303 |
| 2021 10 | 282 | 69 | 351 |
| 2021 9 | 232 | 59 | 291 |
| 2021 8 | 223 | 42 | 265 |
| 2021 7 | 201 | 49 | 250 |
| 2021 6 | 213 | 24 | 237 |
| 2021 5 | 207 | 39 | 246 |
| 2021 4 | 366 | 76 | 442 |
| 2021 3 | 212 | 42 | 254 |
| 2021 2 | 180 | 14 | 194 |
| 2020 1 | 138 | 37 | 175 |
| 2020 12 | 165 | 18 | 183 |
| 2020 11 | 127 | 27 | 154 |
| 2020 10 | 136 | 10 | 146 |
| 2020 9 | 160 | 25 | 185 |
| 2020 8 | 131 | 16 | 147 |
| 2020 7 | 132 | 27 | 159 |
| 2020 6 | 169 | 41 | 210 |
| 2020 5 | 135 | 29 | 164 |
| 2020 4 | 212 | 32 | 244 |
| 2020 3 | 226 | 24 | 250 |
| 2020 2 | 246 | 23 | 269 |
| 2020 1 | 222 | 28 | 250 |
| 2019 12 | 217 | 24 | 241 |
| 2019 11 | 246 | 36 | 282 |
| 2019 10 | 306 | 29 | 335 |
| 2019 9 | 449 | 41 | 490 |
| 2019 8 | 237 | 14 | 251 |
| 2019 7 | 249 | 30 | 279 |
| 2019 6 | 231 | 12 | 243 |
| 2019 5 | 218 | 18 | 236 |
| 2019 4 | 302 | 38 | 340 |
| 2019 3 | 198 | 31 | 229 |
| 2019 2 | 194 | 30 | 224 |
| 2019 1 | 150 | 21 | 171 |
| 2018 12 | 332 | 42 | 374 |
| 2018 11 | 430 | 23 | 453 |
| 2018 10 | 448 | 21 | 469 |
| 2018 9 | 586 | 23 | 609 |
| 2018 8 | 480 | 27 | 507 |
| 2018 7 | 403 | 15 | 418 |
| 2018 6 | 181 | 16 | 197 |
| 2018 5 | 249 | 13 | 262 |
| 2018 4 | 191 | 10 | 201 |
| 2018 3 | 179 | 14 | 193 |
| 2018 2 | 160 | 11 | 171 |
| 2018 1 | 185 | 6 | 191 |
| 2017 12 | 196 | 10 | 206 |
| 2017 11 | 188 | 7 | 195 |
| 2017 10 | 129 | 8 | 137 |
| 2017 9 | 127 | 14 | 141 |
| 2017 8 | 142 | 13 | 155 |
| 2017 7 | 110 | 13 | 123 |
| 2017 6 | 138 | 9 | 147 |
| 2017 5 | 149 | 11 | 160 |
| 2017 4 | 112 | 12 | 124 |
| 2017 3 | 132 | 16 | 148 |
| 2017 2 | 361 | 20 | 381 |
| 2016 1 | 114 | 12 | 126 |
| 2016 12 | 152 | 9 | 161 |
| 2016 11 | 199 | 10 | 209 |
| 2016 10 | 214 | 12 | 226 |
| 2016 9 | 336 | 10 | 346 |
| 2016 8 | 411 | 5 | 416 |
| 2016 7 | 312 | 18 | 330 |
| 2016 6 | 171 | 0 | 171 |
| 2016 5 | 177 | 0 | 177 |
| 2016 4 | 133 | 0 | 133 |
| 2016 3 | 136 | 0 | 136 |
| 2016 2 | 156 | 0 | 156 |
| 2015 1 | 162 | 0 | 162 |
| 2015 12 | 184 | 0 | 184 |
| 2015 11 | 154 | 0 | 154 |
| 2015 10 | 157 | 0 | 157 |
| 2015 9 | 174 | 0 | 174 |
| 2015 8 | 173 | 0 | 173 |
| 2015 7 | 185 | 0 | 185 |
| 2015 6 | 135 | 0 | 135 |
| 2015 5 | 230 | 0 | 230 |
| 2015 4 | 52 | 0 | 52 |
| 2015 2 | 6328 | 0 | 6328 |
Mostrar todo
